Use of imidazole and indole compounds as inhibitors of nitric oxide synthase
US6087363A · kind A · utility
2Cited by
5References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 1999 |
| Grant date | Jul 11, 2000 |
| Priority date | — |
| Expiry date | Jul 16, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/497
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Imidazole and indole compounds were found to inhibit neural nitric oxide synthase (bNOS) activity. Nortopsentin-C inhibited bNOS as well as calcineurin activities suggesting that its actions are directed against calmodulin, a co-factor common to these two enzymes. Two indole compounds, as well as dragmacidin-D, inhibited bNOS, but not calcineurin, activity. Murine macrophage viability and induced NOS (iNOS) activity in cultured cells was also unaffected by these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.